{"id":3744,"date":"2025-03-31T18:11:48","date_gmt":"2025-03-31T18:11:48","guid":{"rendered":"https:\/\/kidneydiseaseclinic.net\/kdc\/bevacizumab1-txt\/"},"modified":"2025-03-31T18:11:48","modified_gmt":"2025-03-31T18:11:48","slug":"bevacizumab1-txt","status":"publish","type":"post","link":"https:\/\/kidneydiseaseclinic.net\/kdc\/bevacizumab1-txt\/","title":{"rendered":"Bevacizumab1.txt"},"content":{"rendered":"

Bevacizumab<\/h1>\n

CLINICAL USE <\/H3>
\nTreatment of metastatic carcinoma of the colon or rectum

DOSE IN NORMAL RENAL FUNCTION <\/H3>5 mg\/kg every 14 days

PHARMACOKINETICS <\/H3>
  • Molecular weight &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp :149 000<\/li>\n
  • %Protein binding &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp :No data<\/li>\n
  • %Excreted unchanged in urine &nbsp &nbsp : No data<\/li>\n

  • Volume of distribution (L\/kg) &nbsp &nbsp &nbsp :0.046<\/li>\n

  • half-life \u2013 normal\/ESRD (hrs)&nbsp &nbsp &nbsp :11\u201350 days (average 20 days)

    DOSE IN RENAL IMPAIRMENT <\/H3>

    GFR (mL\/MIN)<\/H4>
  • 20 to 50 &nbsp &nbsp : Use with caution
  • 10 to 20 &nbsp &nbsp : Use with caution
  • <10 &nbsp &nbsp &nbsp &nbsp &nbsp : Use with caution

    DOSE IN PATIENTS UNDERGOING RENAL REPLACEMENT THERAPIES <\/H3>
  • CAPD &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp:Not dialysed. Use with caution. See \u2018Other Information\u2019<\/p>\n
  • HD &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp :Not dialysed. Use with caution. See \u2018Other Information\u2019
  • HDF\/high flux &nbsp :Not dialysed. Use with caution. See \u2018Other Information\u2019
  • CAV\/VVHD &nbsp &nbsp &nbsp:Not dialysed. Use with caution. See \u2018Other Information\u2019

    IMPORTANT DRUG INTERACTIONS <\/H3>Potentially hazardous interactions with other drugsNone known

    ADMINISTRATION <\/H3>

    Reconstition<\/H4>\u2013

    Route <\/H4>

    IV infusion <\/H4>

    Rate of Administration <\/H4>30\u201390 minutes depending on how the patient tolerates it

    Comments<\/H4>Dilute in 100 mL of sodium chloride 0.9% DO NOT mix with glucose solutions

    OTHER INFORMATION <\/H4>\n
  • Increased incidence of hypertension has been seen with treatment\n
  • People with a history of hypertension may be at an increased risk of proteinuria.\n
  • Discontinue therapy in patients with Grade 4 proteinuria (nephrotic syndrome)\n
  • Can delay wound healing Bevacizumab has been used in a haemodialysis patient at a dose of 5 mg\/kg every 14 days.
    \n","protected":false},"excerpt":{"rendered":"

    Bevacizumab CLINICAL USE Treatment of metastatic carcinoma of the colon<\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"","ping_status":"","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[1],"tags":[7],"class_list":["post-3744","post","type-post","status-publish","format-standard","hentry","category-blog","tag-post-by-auto-php"],"_links":{"self":[{"href":"https:\/\/kidneydiseaseclinic.net\/kdc\/wp-json\/wp\/v2\/posts\/3744","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/kidneydiseaseclinic.net\/kdc\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/kidneydiseaseclinic.net\/kdc\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/kidneydiseaseclinic.net\/kdc\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/kidneydiseaseclinic.net\/kdc\/wp-json\/wp\/v2\/comments?post=3744"}],"version-history":[{"count":0,"href":"https:\/\/kidneydiseaseclinic.net\/kdc\/wp-json\/wp\/v2\/posts\/3744\/revisions"}],"wp:attachment":[{"href":"https:\/\/kidneydiseaseclinic.net\/kdc\/wp-json\/wp\/v2\/media?parent=3744"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/kidneydiseaseclinic.net\/kdc\/wp-json\/wp\/v2\/categories?post=3744"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/kidneydiseaseclinic.net\/kdc\/wp-json\/wp\/v2\/tags?post=3744"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}